I3C Estrogen Metabolism.

Indole-3-carbinol condenses under stomach acid into DIM, the form that actually circulates. Carrying both makes the delivered amount less dependent on stomach acidity.

Indole-3-carbinol favours the 2-hydroxy estrogen route, and glucarate limits gut beta-glucuronidase so glucuronide conjugates are not unpicked before excretion. The pair covers consecutive steps of one clearance sequence.

Catechol estrogens produced downstream are methylated by COMT using S-adenosylmethionine. Betaine remethylates homocysteine to methionine and keeps that donor pool topped up.

COMT needs magnesium at the active site to carry out methyl transfer. Adequate magnesium lets the methylation step keep pace with the hydroxylation shift.

Methylfolate feeds the carbon that regenerates methionine and therefore S-adenosylmethionine. That pool drives the COMT step acting on catechol metabolites.

Gut bacteria convert flax secoisolariciresinol into enterolignans that bind weakly at estrogen receptors and influence sex hormone binding globulin. That is a different point of the same hormone handling picture from the hydroxylation routing indoles affect.

Sulforaphane drives Nrf2 dependent phase II enzyme expression while indole-3-carbinol shifts phase I hydroxylation routing. Together they cover induction of conjugating capacity as well as which metabolite is formed.

Cruciferous indoles induce CYP1A2, the main route for caffeine breakdown. Regular indole intake can shorten how long a caffeine dose is felt.

Indole-3-carbinol only becomes its active species through acid-catalysed condensation in the stomach, forming diindolylmethane and larger oligomers. Gastric acidity is therefore part of the mechanism and not merely part of digestion. Anything that raises gastric pH shifts how much conversion happens, which is why an acid-supporting ingredient is mechanistically relevant here.

Indole-3-carbinol comes from glucobrassicin, a glucosinolate that myrosinase hydrolyses when cruciferous tissue is crushed or chewed. A sprout extract that retains active myrosinase supplies both the precursor and the enzyme. It also brings glucoraphanin and sulforaphane, which act through Nrf2 rather than through the aryl hydrocarbon receptor, so the two cover different arms of phase I and phase II handling.

The 2-hydroxylation that indole condensation products favour produces catechol estrogens, and catechol-O-methyltransferase disposes of those by methylation using S-adenosylmethionine as the methyl donor. Without that methylation step catechols can redox-cycle rather than clear. SAMe supplies the donor directly, which is why the two sit on the same sequence.

Methionine is the precursor from which S-adenosylmethionine is made, so it feeds the same methylation capacity that catechol clearance draws on. It is an upstream input rather than a parallel one. This is settled one-carbon biochemistry, not a claim about a measured combination.

Methionine synthase needs methylcobalamin to move a methyl group from 5-methyltetrahydrofolate onto homocysteine, regenerating methionine and with it the SAM pool. That places B12 on the same methylation route the methylfolate already stored against this page supports. All three are inputs to one capacity rather than three separate effects.

Pyridoxal-5-phosphate runs the transsulfuration branch that clears homocysteine toward cysteine, and it is a cofactor for serine hydroxymethyltransferase feeding the folate cycle. Both keep the methylation pool turning over. Its relevance to estrogen metabolite handling is through that pathway, not through any direct action on estrogen.

Cytochrome P450 reductase, the flavoprotein that feeds electrons to every CYP enzyme including CYP1A1 and CYP1A2, requires FAD and FMN. Riboflavin is the dietary source of both. Riboflavin is also the cofactor for the enzyme that makes the active form of folate, so it sits on the methylation side as well.

CYP-mediated hydroxylation consumes NADPH at every catalytic cycle, and NADPH comes from the NAD pool that niacin supplies. So the phase I hydroxylation step this ingredient is proposed to shift is directly NADPH-dependent. Established enzymology rather than a supplement interaction.

Catechol estrogens and their quinone forms are conjugated with glutathione as an alternative disposal route to methylation. Glutathione availability therefore determines part of the fate of the metabolites this pathway produces. Oral glutathione's own absorption is a separate and contested question, so the pathway logic is stronger than the delivery evidence.

N-acetylcysteine supplies cysteine, the rate-limiting amino acid for glutathione synthesis, which is the conjugation route for catechol quinones. That makes it an upstream input to phase II capacity. The step is established; how much a given dose raises hepatic glutathione in a person varies.

Glycine is one of the three amino acids of glutathione and is itself a conjugating group in phase II handling. It supports the same conjugation capacity that estrogen metabolite clearance uses. Straightforward substrate biochemistry.

Silymarin flavonolignans modulate phase II conjugating enzymes and hepatic UDP-glucuronosyltransferase activity in laboratory systems. Glucuronidation is the main exit route for estrogen metabolites into bile. The direction and size of that effect in people is not settled, so this is a modulating pairing rather than an additive one.

EGCG and other catechins are substrates and inhibitors of catechol-O-methyltransferase, the enzyme that methylates the 2-hydroxy estrogen metabolites this pathway generates. Competing for that enzyme could slow catechol clearance rather than speed it. Worth flagging as a genuine anti-synergy in a formula that pairs the two.

Quercetin is a preferred substrate for both sulfotransferases and catechol-O-methyltransferase, and it inhibits several CYP1 family enzymes in vitro. Both actions sit on the same phase I and phase II steps as the indole condensation products. The interaction is mechanistically clear and has not been measured in a combination trial.

Curcumin activates Nrf2 and shifts phase II conjugating enzyme expression in cell and animal systems, while also inhibiting several phase I enzymes. Layered on an aryl hydrocarbon receptor ligand the net effect on any one metabolite ratio is not predictable from the parts. Formulas combine them often, which is exactly why the uncertainty is worth stating.

Resveratrol is an aryl hydrocarbon receptor antagonist in several cell systems, and it also interacts with estrogen receptors as a partial agonist. Both of those touch the same machinery an indole condensation product works through, and antagonism at that receptor points the opposite way. This is a modulating pairing whose net direction has not been resolved in people.

Estrogen metabolites leave the liver conjugated into bile, and bacterial beta-glucuronidase can cut those conjugates so the free metabolite is reabsorbed. The composition of the gut community therefore sets how much is recycled rather than excreted. Which strains raise or lower that activity is strain-specific and not settled, so the relationship is real and the direction is not general.

Fermentable fructans change the composition and metabolic output of the colonic community, including the beta-glucuronidase activity that deconjugates biliary estrogen metabolites. That is a plausible route to influencing how much is recycled. The size and direction of the effect on any human estrogen measure has not been established.

Bulk-forming fibre shortens transit and binds bile components, which reduces the window for bacterial deconjugation and reabsorption of biliary metabolites. That mechanism is established for bile acids and is inferred, not measured, for estrogen conjugates. Stated as the inference it is.

MTHFR requires FAD, made from riboflavin, to produce the methylfolate that feeds methionine synthase. Riboflavin also supplies FAD for cytochrome P450 reductase, the flavoprotein that delivers electrons to the CYP1A1 and CYP1A2 enzymes performing 2-hydroxylation. It sits on both halves of this pathway.

Beta-glucuronidase activity varies widely between gut bacterial species, so composition affects how much conjugated estrogen is deconjugated and reabsorbed in the colon. Naming a specific strain here identifies the mechanism, not a demonstrated shift in any metabolite ratio. No trial has paired this strain with indole-3-carbinol.

Resistant starch fermentation produces butyrate and lowers colonic pH, conditions that suppress the activity of some bacterial beta-glucuronidases. That places it on the reabsorption side of estrogen handling. The mechanism is established fermentation biochemistry; the estrogen-specific consequence has not been measured.

Small human studies have reported that boron supplementation changes measured concentrations of circulating steroid hormones, including the fraction not bound to carrier proteins. Those are hormone markers in small samples, not outcomes, and the mechanism is unclear. It is named because anything altering free hormone concentrations changes the substrate available to the metabolising enzymes.

Licorice contains constituents with weak estrogen receptor affinity and it also affects steroid-metabolising enzymes including 11-beta-hydroxysteroid dehydrogenase. Combining it with something acting on estrogen metabolising enzymes creates an interaction on the same axis at a different point. Both sides of this pairing are poorly quantified in people.

Black cohosh constituents act on serotonergic and possibly estrogen-responsive signalling, with the mechanism still argued in the literature. It appears in the same formulas as indole-3-carbinol, which is reason enough to name the overlap on the hormonal axis. Neither the mechanism nor the combination is settled.